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Hepatitis E virus (HEV) is a major human pathogen in much of the developing world. It is a positive-strand
RNA virus with a 7.5-kb polyadenylated genome consisting of three open reading frames (ORFs). In the
absence of an in vitro culture system, the replication and expression strategy of HEV and the nature of its
encoded polypeptides are not well understood. We have expressed the two ORFs constituting the structural
portion of the HEV genome in COS-1 cells by using simian virus 40-based expression vectors and in vitro by
using a coupled transcription-translation system. We show here that the major capsid protein, encoded by
ORF2, is an 88-kDa glycoprotein which is expressed intracellularly as well as on the cell surface and has the
potential to form noncovalent homodimers. It is synthesized as a precursor (ppORF2) which is processed
through signal sequence cleavage into the mature protein (pORF2), which is then glycosylated (gpORF2). The
minor protein, pORF3, encoded by ORF3 is a 13.5-kDa nonglycosylated protein expressed intracellularly and
does not show any major processing. pORF3 interacts with a cellular protein of about 18 kDa which we call 3IP,
the pORF3-interacting protein. The significance of these findings are discussed in light of an existing model
of HEV genome replication and expression.
Hepatitis E virus (HEV) is responsible for large epidemics
and rampant sporadic cases of acute viral hepatitis in much of
the developing world, where it is endemic (3, 11, 20, 28). In
developed countries, this disease is seen primarily in travellers
to areas where it is endemic. Though largely a self-limited
infection, it results in significant morbidity and mortality, es-
pecially among pregnant women (12) and in situations in which
coinfection with other hepatic viruses may occur (17).
The viral genome has been cloned and sequenced from a
number of geographically distinct HEV strains and shows a
high degree of nucleotide and amino acid sequence conserva-
tion (1, 2, 6, 24, 26). The genome is a positive-stranded RNA
of about 7.5 kb with short 59 and 39 noncoding regions span-
ning a coding region that includes three open reading frames
(ORFs) (24) (Fig. 1). Of these, the N-terminal ORF1 of about
5 kb is predicted to code for the putative nonstructural pro-
teins, that include a methyltransferase, a papain-like cysteine
protease, a replicase, and an RNA-dependent RNA poly-
merase (13). The C-terminal region of about 2.4 kb codes for
two putative structural proteins, pORF2 and pORF3, the prod-
ucts of ORF2 and ORF3, respectively (Fig. 1). The fact that
both of these structural-region ORFs are expressed during
viral infection is demonstrated by the presence of antibodies in
infected humans directed against epitopes present on pORF2
as well as on pORF3 (9, 10, 16, 18, 29).
So far, HEV has not been classified conclusively into any
virus family. Its provisional classification into the Caliciviridae
family was based primarily on the presence of morphological
features similar to those of other agents in this family (3, 14).
However, the genome organization shows a major difference in
that the small ORF, ORF3, is located mostly within ORF2 in
HEV, whereas it is C terminal in calciviruses like the Norwalk
agent (8). There has also been a suggestion that HEV is a
nonenveloped ‘‘alpha-like’’ virus (13, 21). This is based on the
presence of homologous regions across the genome (13), the
detection of subgenomic HEV transcripts in the livers of ex-
perimentally infected monkeys (24), and the presence of a
nucleotide sequence stretch in the HEV genome that is ho-
mologous to alphaviral junction sequences (21). A conclusive
classification of HEV awaits further knowledge of its expres-
sion and replication strategy and of the nature, processing, and
properties of its component proteins.
The inability to grow HEV in culture has so far precluded
any such studies. No information on the nature and properties
of the viral antigens is available. In this work, we expressed
pORF2 and pORF3 in cultured animal cells and used this
expression system to study the properties and interactions of
these viral proteins.
MATERIALS AND METHODS
Construction of expression vectors. The cloning of ORF2 and ORF3 from an
Indian strain of HEV has been described elsewhere (18). This sequence has been
deposited in the GenBank database under accession number U22532. The ex-
pression plasmid used in this study, pSGI, is a modification of plasmid pSG5
(Stratagene) in which a synthetic sequence was inserted between the EcoRI and
BamHI sites. This resulted in a vector with a number of unique cloning sites,
including EcoRI-SmaI-SacI-EcoRV-KpnI-HindIII-PstI-XhoI-NaeI-NotI-BamHI.
Expression from this vector in animal cells is dependent on the simian virus 40
early promoter-enhancer region, and expression in vitro is dependent on the
bacteriophage T7 promoter. For the construction of expression vector pSG-
ORF2, a 2-kb NcoI-BamHI fragment encompassing the entire HEV ORF2
region was isolated, end filled with the Klenow fragment of DNA polymerase,
and cloned into the EcoRV site within the polylinker region of plasmid pSGI.
For the construction of expression vector pSG-ORF3, a 700-bp BamHI-EcoRI
fragment encompassing the complete HEV ORF3 was isolated and similarly
cloned into plasmid pSGI. The schematics and details of vector construction are
presented in Fig. 1.
Transfection and labeling of cultured cells. COS-1, HepG2, and Huh-7 cells
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing
10% fetal bovine serum and 20 mg of gentamicin per ml. Cells were transfected
at about 50% confluency with plasmid DNA by using Lipofectin (GIBCO-BRL)
according to the manufacturer’s guidelines. For each 60-mm-diameter culture
dish, 2.5 mg of DNA and 10 ml of Lipofectin were used in 1.2 ml of DMEM
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without serum or antibiotics, and DNA uptake allowed to proceed for 6 h at 378C
in a CO2 incubator. Forty hours posttransfection, cells were washed with 3 ml of
methionine-deficient DMEM (GIBCO-BRL) and metabolically labeled with
[35S]methionine (Amersham), with each 60-mm-diameter plate receiving 150
mCi of label in 1 ml of methionine-deficient DMEM. After a 4-h labeling period,
cells were washed with ice-cold phosphate-buffered saline (PBS) and harvested
for further analysis. Besides HEV ORF-containing expression plasmids, each
experiment also included a control (or mock) transfection in which the same
amount of the parent vector, pSGI, was used.
Immunofluorescence. At about 44 h posttransfection, cells were fed with 1 ml
of fresh medium, kept on ice for 30 min, and scraped off with a disposable
scraper. Staining was done with a 1:100 dilution of polyclonal antibodies raised
in rabbits against purified pORF2 and pORF3 polypeptides expressed in Esch-
erichia coli (18). For surface immunofluorescence, cells in suspension were in-
cubated at 48C for 1 h with diluted antibody in DMEM containing 10% fetal
bovine serum. Cells were then washed three times with the above medium by
centrifugation in a cold centrifuge (Hermle GmbH) at 1,000 rpm. Washed cells
were incubated with a 1:100 dilution of anti-rabbit immunoglobulin G-fluores-
cein isothiocyanate conjugate at 48C for 1 h and subsequently washed as de-
scribed above. For intracellular localization, 105 cells in 0.5 ml were centrifuged
onto glass slides at 2,000 rpm in a cytocentrifuge (Shandon). Cells were fixed in
acetone and stained as described above, except that antibody dilutions and
washings were carried out in PBS (pH 7.2). Stained cells were observed with an
epifluorescence microscope (Nikon).
Immunoprecipitation. Transfected, PBS-washed COS-1 cells were harvested
directly in 0.5 ml of RIPA buffer (10 mM Tris-HCl [pH 8.0], 140 mM NaCl, 5
mM iodoacetamide, 0.5% Triton X-100, 1% sodium deoxycholate, 0.1% sodium
dodecyl sulfate [SDS], 2 mM phenylmethylsulfonyl fluoride) after incubation on
ice for 15 to 30 min. Lysates were clarified at 10,000 3 g for 10 min, and the
supernatant was incubated on ice for 1 h with 5 ml of rabbit antiserum. For
immunoprecipitation with HEV immune serum, 10 ml of pooled serum from
patients with hepatitis E was used. The mix was centrifuged again as described
above, and the supernatant was removed to a fresh tube. To this was added 100
ml of a 10% suspension of RIPA buffer-washed protein A-Sepharose beads
(Pharmacia, Uppsala, Sweden), and the mixture was incubated with constant
shaking at 48C for 1 h. The beads were washed five times, each time with 0.5 ml
of RIPA buffer, after being centrifuged in a Costar microcentrifuge at 10,000 rpm
for 10 s. Washed beads were resuspended in 50 ml of SDS gel loading buffer (50
mM Tris-HCl [pH 6.8], 5% 2-mercaptoethanol, 2% SDS, 0.1% bromophenol
blue, 10% glycerol), heated at 1008C for 2 min, and centrifuged, and the super-
natants were subjected to SDS-polyacrylamide gel electrophoresis (PAGE). Af-
ter electrophoresis, the gels were soaked in 0.5 M sodium salicylate for 1 h, dried,
and exposed to X-ray film.
For the immunoprecipitation of antigens expressed in HepG2 and Huh-7 cells,
transfected and PBS-washed cells were harvested in 1 ml of RIPA buffer. Clar-
ified lysates were incubated with 10 ml of preimmune rabbit serum on ice for 1
FIG. 1. HEV ORFs and cloning strategy. The three ORFs and their relative
positions along the HEV genomic polyadenylated RNA are indicated. The ex-
pression vectors were constructed by subcloning the NcoI-BamHI (for ORF2) or
BamHI-EcoRI (for ORF3) fragment at the EcoRV site within the polylinker of
plasmid pSGI. The vector backgrounds for ORF2 and ORF3 fragments (shaded
regions) are shown. ATG initiator codons (open bars), part of the NcoI site, are
indicated. Closed bars represent translation termination sequences. SV40 Pr,
simian virus 40 promoter-enhancer and origin of replication sequences; T7 Pr,
bacteriophage T7 promoter.
FIG. 2. Indirect immunofluorescence of HEV antigens. Immunofluorescence analysis was carried out on COS-1 cells transfected with either plasmid pSG-ORF2
(A and B) or plasmid pSG-ORF3 (C), as described in the text. Transfected cells were stained in solution for surface immunofluorescence (A) or after cytospin and
fixation for intracellular immunofluorescence (B and C).
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h with the subsequent addition of 50 ml of a 50% protein A-Sepharose suspen-
sion. The mixture was then incubated at 48C with shaking for 1 h. The beads were
centrifuged down, and precleared lysates were subjected to immunoprecipitation
with 10 ml of the specific antiserum as described above for COS-1 cells.
Cell fractionation. COS-1 cells that had been transfected and labeled with
[35S]methionine as described above were washed once with PBS and then
scraped off the plate into 1 ml of PBS. After centrifugation, cell pellets equivalent
to each 60-mm-diameter plate were resuspended in 0.5 ml of lysis buffer (10 mM
Tris-HCl [pH 8.0], 140 mM NaCl, 5 mM iodoacetamide, 0.5% Triton X-100, 2
mM phenylmethylsulfonyl fluoride) and kept on ice for 1 h. Lysates were cen-
trifuged in a Biofuge RS microcentrifuge (Heraeus Sepratech, GmbH) at 13,000
rpm for 30 min. The supernatant (cytoplasmic fraction) was removed to a fresh
tube, and 50 ml of a 103 DOC-SDS solution (10% sodium deoxycholate, 1%
SDS) was added to it. The pellets were washed once with 0.5 ml of lysis buffer as
described above. Washed pellets (nuclear fraction) were resuspended in 0.5 ml of
RIPA buffer. Both fractions were immunoprecipitated as described above.
Tunicamycin treatment. At 40 h posttransfection, cells were shifted to 1 ml of
methionine-deficient DMEM without or with 10 mg of tunicamycin (Boehringer
Mannheim GmBH) for 1 h. Cells were then labeled with [35S]methionine for 4
h, as described above, in the absence or presence of 10 mg of tunicamycin per ml.
Total cell lysates in RIPA buffer were immunoprecipitated as described above.
Pulse-chase analysis. At 40 h posttransfection, cells were shifted to 3 ml of
methionine-deficient DMEM for 1 h. Labeling was performed as described
above, except that 300 mCi of [35S]methionine per 60-mm-diameter plate was
used and the labeling time was 20 min. After the removal of the labeling mix, 3
ml of culture medium was added and cells were harvested either immediately or
after a chase of 30 min or 4 h. Total lysates in RIPA buffer were immunopre-
cipitated as described above.
In vitro translation. A coupled transcription-translation system (TNT; Pro-
mega) with bacteriophage T7 RNA polymerase was used for in vitro syntheses of
polypeptides from pSG-ORF2 and pSG-ORF3 plasmid templates according to
the supplier’s guidelines. For cotranslational processing, 2 ml of canine pancre-
atic membranes (Promega) was also included in the 25-ml in vitro transcription-
translation reaction. [35S]methionine-labeled polypeptides synthesized in vitro
were separated by SDS-PAGE either directly or after immunoprecipitation and
visualized by fluorography.
Endoglycosidase treatment. After the immunoprecipitation described above,
the protein A-Sepharose beads containing bound antigen were resuspended in 20
ml of 0.5% SDS–1% 2-mercaptoethanol and heated at 1008C for 10 min. To this
was added 2.5 ml of 0.5 M sodium citrate (pH 5.5) and 2 ml of endoglycosidase
H (500 U/ml; New England Biolabs, Beverly, Mass.). No enzyme was added to
control samples. After digestion at 378C for 2 h, 25 ml of 23 SDS gel loading
buffer was added, and the samples were boiled for 5 min and analyzed by
separation on SDS–7.5% PAGE gels and fluorography.
FIG. 3. Expression of HEV antigens. (A and B) Two independent clones of pSG-ORF2 (A), pSG-ORF3 (B), or the parent vector pSGI (Mock [A and B]) were
transfected into COS-1 cells. Transfected cells were labeled with [35S]methionine, lysed, and fractionated into cytoplasmic (Cyto) and nuclear fractions, and the total
lysates or fractions were immunoprecipitated with anti-pORF2 antiserum (A) or anti-pORF3 antiserum (B), as described in the text. Washed immunoprecipitates were
separated by either SDS–10% PAGE (A) or SDS–15% PAGE (B) and visualized by fluorography. Lanes Mol. Wt., molecular size markers (in kilodaltons). (C) Two
independent clones of plasmid pSG-ORF2 (ORF2-1 and ORF2-14), plasmid pSG-ORF3 (ORF3-1 and ORF3-2), and the parent vector (Mock) were expressed in a
coupled in vitro transcription-translation system. The reaction mix was immunoprecipitated with anti-pORF2 or anti-pORF3 antiserum, separated by SDS–12% PAGE,
and visualized by fluorography. The positions of pORF2, pORF3, the pORF3 dimer, and size markers (in kilodaltons) are indicated.
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For an analysis of glycosylation in vitro, to 10 ml of the transcription-transla-
tion mixture was added 2 ml of denaturing buffer (3% SDS, 6% 2-mercaptoetha-
nol) and the mixture was heated at 1008C for 10 min. To this was added 20 ml of
reaction buffer (75 mM citrate-phosphate [pH 5.0], 100 mM EDTA, 5% Triton
X-100, 1% 2-mercaptoethanol) and 0.4 U of endoglycosidase F (Boehringer
Mannheim GmbH), and the reaction was incubated at 378C. The control reaction
included everything but the enzyme. Aliquots (10 ml) were removed at various
times, inactivated by being boiled in 40 ml of SDS gel loading buffer, and kept
frozen at2708C. Samples were analyzed by separation on SDS–7.5% PAGE gels
and fluorography.
RESULTS
Expression of HEV proteins. The expression vectors pSG-
ORF2 and pSG-ORF3 contain the HEV ORFs driven by the
simian virus 40 control elements, including the ori sequences.
These vectors are capable of replication to high copy numbers
in T-antigen-producing monkey kidney COS-1 cells and should
express high levels of the proteins encoded by HEV ORFs.
Transfected cells were scored for antigen expression by immu-
nofluorescence analysis with specific polyclonal antibodies.
The results presented in Fig. 2 show that both pORF2 and
pORF3 are expressed in transfected cells. pORF2 was found
on the cell surface (Fig. 2A) as well as in the cytoplasm (Fig.
2B). On the other hand, pORF3 was found only in the cyto-
plasm (Fig. 2C). Controls with preimmune sera did not show
any staining on transfected COS-1 cells (data not shown). It is
evident that antisera do not react with cellular components
from the staining of only a fraction of the transfected cells in a
given field, in agreement with the expected transfection effi-
ciency of about 40 to 50%.
Total lysates from COS-1 cells transfected with the appro-
priate vectors and metabolically labeled with [35S]methionine
were also subjected to immunoprecipitation with polyclonal
antisera. Cells transfected with two independent clones of plas-
mid pSG-ORF2 showed the specific immunoprecipitation of
the 74- to 88-kDa proteins absent in cells transfected with the
parent vector pSGI (Fig. 3A). Similarly, a 13.5-kDa protein
was found in cells transfected with two independent clones of
plasmid pSG-ORF3 but was not found in cells transfected with
the parent vector (Fig. 3B). Both pORF2 and pORF3 were
also found in Huh-7 hepatoma cells transfected with the ex-
pression vectors, albeit at a level much reduced in comparison
with that in COS-1 cells (data not shown).
Subcellular fractionation of transfected COS-1 cells showed
that both pORF2 (Fig. 3A) and pORF3 (Fig. 3B) were present
in the cytoplasmic fraction, supporting the observations of im-
munofluorescence studies (Fig. 2). A trace amount of pORF3
was also found in the nuclear fraction. Neither protein was
found to be secreted into the culture medium (data not
shown).
The expression of both proteins was also carried out in a
coupled in vitro transcription-translation system. Again, both
independent clones of pSG-ORF2 as well as those of pSG-
ORF3 expressed the respective proteins, as judged by immu-
noprecipitation with specific antisera (Fig. 3C). In total trans-
lation reactions without immunoprecipitation, pORF2 and
pORF3 were the major protein bands, accounting for.80% of
the synthesized protein (data not shown). The size of pORF2
expressed in vitro was found to be 74 kDa, indicating that the
protein expressed in cultured cells may be subjected to post-
translational modifications (Fig. 3A). The in vitro-expressed
pORF3, like its cell-expressed counterpart (Fig. 3B), was 13.5
kDa. In the in vitro system, however, a pORF3 species of about
28 kDa was evident (Fig. 3C); it was reproducibly absent when
pORF3 was expressed in transfected cells. The fraction of this
28-kDa form of pORF3 varied between different in vitro ex-
pression experiments. Furthermore, it was observed that rabbit
polyclonal anti-pORF3 antiserum immunoprecipitated the 28-
kDa form with a lower efficiency compared with that of the
13.5-kDa form of pORF3.
Both HEV antigens from lysates of pSG-ORF2- or pSG-
ORF3-transfected COS-1 cells also immunoprecipitated with
pooled HEV immune serum obtained from patients with hep-
atitis E (Fig. 4). No such precipitation was observed from
lysates of mock-transfected COS-1 cells. These results further
authenticate the natures of the expressed proteins.
pORF2 is a glycoprotein. The glycoprotein status of pORF2
and pORF3 was evaluated in experiments in which tunicamy-
cin was used to inhibit glycosylation in transfected cells. The
expression of higher-molecular-weight forms of pORF2 was
quantitatively inhibited by tunicamycin (Fig. 5A), suggesting
that the 74-kDa form represents the nonglycosylated protein
and that the two distinctly larger forms, about 82 and 88 kDa,
represent the glycosylated protein, perhaps with different ex-
tents of glycosylation. In HepG2 cells as well, treatment with
tunicamycin led to a shift from the higher-molecular-weight
form of gpORF2 to the faster-moving form of pORF2 (Fig.
5B). Tunicamycin treatment had no effect on pORF3 ex-
pressed either in COS-1 cells (Fig. 5C) or in HepG2 cells (Fig.
5D), suggesting that this protein is not glycosylated.
To further confirm the glycoprotein nature of pORF2, the
protein expressed in COS-1 or HepG2 cells in the absence or
presence of tunicamycin was subjected to endoglycosidase di-
gestion. As shown in Fig. 6, gpORF2 expressed in both COS-1
and HepG2 cells was completely reduced to the nonglycosy-
lated pORF2 form with endoglycosidase H, an effect similar to
FIG. 4. Immunoprecipitation with HEV immune serum. COS-1 cells were
transfected with the indicated plasmids and labeled with [35S]methionine, and
lysates were immunoprecipitated with pooled HEV immune serum from patients
with hepatitis E. Immunoprecipitates were separated by SDS–7.5% PAGE (A)
or SDS–15% PAGE (B) and visualized by fluorography. The positions of pORF2
(A) and pORF3 (B) are indicated by arrows. The positions of size markers (in
kilodaltons) are also indicated.
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that observed with tunicamycin treatment. These results un-
equivocally demonstrate that pORF2 is a glycoprotein and that
its glycosylation is not an artifact of overexpression in COS-1
cells, which are not the natural target cells for HEV infection.
Processing of HEV proteins. The processing of pORF2 and
pORF3 was studied in transfected cells in culture, as well as in
vitro. In a pulse-chase experiment after a 20-min pulse of
[35S]methionine, a single 82-kDa form of pORF2 was predom-
inant. After a 30-min chase with unlabeled methionine, three
forms of pORF2 were found, while after a 4-h chase, only the
74- and 88-kDa forms were apparent. At this stage, the 88-kDa
form of pORF2 was predominant. These results (Fig. 7A)
suggest that the ORF2-encoded protein is made as a precursor
(ppORF2), which is first processed into the mature form
(pORF2) and then glycosylated (gpORF2). Similar experi-
ments with pORF3 showed only a single form of the protein
throughout the pulse-chase period (Fig. 7B), suggesting that
this protein does not undergo any major processing. Further,
by comparing the behaviors of these two proteins during the
pulse-chase, the turnover rate of pORF3 appeared to be higher
than that of pORF2.
Cotranslational processing of these two proteins was studied
in vitro in the presence of canine pancreatic membranes (Fig.
8). Apart from pORF2, a slightly larger form was also observed
for in vitro translations carried out in the presence of mem-
branes (Fig. 8A). The fact that the larger form represented
gpORF2 was established by endoglycosidase F digestion, which
resulted in the reduction of gpORF2 into pORF2 (Fig. 8B).
The translation of pORF3 was inhibited by the addition of
membranes. This was a nonspecific effect, as is apparent from
FIG. 5. Effects of tunicamycin on the expression of HEV proteins. (A and C) COS-1 cells were transfected with two independent clones of plasmid pSG-ORF2 (A)
and plasmid pSG-ORF3 (C), with plasmid pSGI (Mock; A and C) as a control. (B and D) HepG2 cells were transfected with pSG-ORF2 (B) and pSG-ORF3 (D), with
plasmid pSGI (Mock; B and D) as a control. The transfected cells were either treated (1) or not treated (2) with tunicamycin, as described in the text. Total cell lysates
were immunoprecipitated, separated by SDS–7.5% PAGE (A and B) or SDS–15% PAGE (C and D) and visualized by fluorography. The positions of size markers (in
kilodaltons), gpORF2, pORF2, and pORF3 are indicated.
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the inhibition of pORF2 translation when translated either
alone or along with pORF3 (Fig. 8A). In spite of the inhibitory
effects of membranes, no cotranslational processing of pORF3
was observed (Fig. 8A). These in vitro results support the
observations made for these two proteins expressed in trans-
fected cells in culture.
Interactions between HEV proteins. Homologous interac-
tions between pORF2 and pORF3 subunits were studied in the
in vitro system. Proteins translated without the addition of
membranes were subjected to SDS-PAGE in the absence or
presence of 2-mercaptoethanol (5%) and/or heat (1008C, 2
min). As shown in Fig. 9A, pORF2 is unaffected by 2-mercap-
toethanol treatment, but the result is a dimeric species if the
sample is not heated prior to electrophoresis. This suggests
that pORF2 forms a noncovalent homodimeric complex. A
distinct doublet observed in the monomeric pORF2 may be the
result of translation from alternate in-frame AUG codons
present at amino acid positions 1, 12, and 16 in the primary
sequence. As observed earlier, in vitro-translated pORF3
showed a predominant 28-kDa form, which was unaffected by
reduction and heating (Fig. 9B).
Heteromeric interactions between subunits of pORF2 and
pORF3 were studied by transfection in COS-1 cells. Cells were
transfected with either pSG-ORF2, pSG-ORF3, or a combi-
nation of two independent clones of each plasmid. [35S]methi-
onine-labeled cell lysates were then immunoprecipitated with
polyclonal antibodies to one protein or the other. The results
(Fig. 9C) show that while anti-pORF2 and anti-pORF3 were
able to precipitate the respective proteins from cotransfected
cells, there was no coimmunoprecipitation of the other protein.
The specificities of the antisera were further substantiated by
the inability of anti-pORF2 to precipitate pORF3 and the
inability of anti-pORF3 to precipitate pORF2. The lack of
coimmunoprecipitation of pORF2 and pORF3 from cotrans-
fected cells suggests that either these two proteins do not
interact with each other in vivo or that the interactions are not
strong enough to survive these immunoprecipitation condi-
tions. Similar results were obtained when in vitro-translated
pORF2 and pORF3 were mixed and cross-immunoprecipi-
tated with these two antisera (data not shown).
pORF3 interacts with a cellular protein. Whenever pORF3
was immunoprecipitated from transfected COS-1 cells, an-
other protein of about 18 kDa coprecipitated with it (Fig. 10A)
(previously observed in Fig. 3B, 5C, and 9C). This protein was
also observed in pORF3 immunoprecipitates from Huh-7 hep-
atoma cells (data not shown), but not those from HepG2 cells
(Fig. 5D). It was designated 3IP, the pORF3-interacting pro-
tein. No such protein was precipitable from mock-transfected
cells (Fig. 10A), showing that it was not the result of antiserum
cross-reactivity. Furthermore, a Western blot (immunoblot) of
lysates from pSG-ORF3-transfected cells was positive for
pORF3 but negative for 3IP (data not shown). By subcellular
fractionation, like pORF3 3IP, was found in the cytoplasmic
fraction (Fig. 3B). It was unaffected by tunicamycin treatment
of cells (Fig. 5C), suggesting that 3IP is not a glycoprotein.
To further establish that 3IP is a cellular protein, in vitro-
translated pORF3 was mixed with [35S]methionine-labeled ly-
sates of untransfected COS-1 cells and the mixture was pre-
cipitated with anti-pORF3 antiserum. A very weak band was
seen in the presence of COS-1 lysates, but it was absent when
no lysates were added (Fig. 10B). As was the pORF3-3IP
interaction in transfected COS-1 cells, the in vitro interaction
was stable for RIPA buffer washing. In fact, identical results
were obtained under washing conditions that were less strin-
gent (10 mM Tris-HCl [pH 8.0], 140 mM Nacl, 0.1% Triton
X-100 [TST buffer]). Quantitatively, however, far less pORF3-
3IP interaction was observed in vitro than in transfected cells.
FIG. 6. Endoglycosidase digestion of gpORF2. HepG2 (A) and COS-1 (B)
cells were transfected with pSG-ORF2, and cells were either treated (1) or not
treated (2) with tunicamycin, as described in the text. [35S]methionine-labeled
cell lysates were immunoprecipitated with rabbit anti-pORF2, and washed im-
munoprecipitates were treated with endoglycosidase H (Endo H) (1) or buffer
alone (2), as described in the text. Digests were then subjected to separation on
SDS–7.5% PAGE gels and to fluorography. The positions of the glycosylated
(gpORF2) and nonglycosylated (pORF2) forms are shown. The positions of size
markers (in kilodaltons) are also indicated.
FIG. 7. Pulse-chase analysis of HEV proteins. COS-1 cells transfected with
either plasmid pSG-ORF2 (A) or plasmid pSG-ORF3 (B) were labeled with
[35S]methionine for 20 min and chased with unlabeled methionine for the times
indicated. Total cell lysates were immunoprecipitated, separated by either SDS–
7.5% PAGE (A) or SDS–15% PAGE (B), and visualized by fluorography. The
size markers (from top to bottom) are 200, 97.4, 69, 46, 30, 21.5, and 14.3 kDa.
The positions of multiple forms of pORF2 and that of pORF3 are indicated.
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DISCUSSION
The genome of HEV has been cloned from multiple geo-
graphically distinct isolates, but the inability to culture this
virus has precluded studies into its molecular nature. Here we
have used a subgenomic fragment expression strategy to gain
an insight into the putative structural proteins of HEV. The
structural region of the HEV genome consists of two ORFs.
These were expressed in COS-1 and HepG2 cells. The former
cell line formed the basis of subsequent analyses as larger
amounts of these proteins were expressed in this cell line
because of replication of the expression vector to high copy
numbers (5, 15). The latter cell line was used to ascertain that
HEV proteins are also expressed in liver cells, the only cells
known to support viral replication.
The major structural protein, pORF2, was found in multiple
forms as a 74- to 88-kDa protein by SDS-PAGE. In vitro
expression showed that the 74-kDa form corresponded to un-
modified pORF2. This is in agreement with the predicted size
of about 72 kDa, based on the 660-amino-acid ORF. On the
basis of tunicamycin inhibition experiments, cotranslational
processing with glycosylation-proficient membranes, and en-
doglycosidase digestion experiments, we have shown that the
approximately 82- and 88-kDa forms are glycosylated versions
of pORF2. This is not an artifact of expression in COS-1 cells,
as is borne out by the glycosylation of pORF2 expressed in
HepG2 cells. Since this is a hepatoma line, it more closely
mimics the natural target cell for HEV infection. In its primary
amino acid sequence, pORF2 contains three potential
N-linked glycosylation sites (Asn-X-Thr/Ser) at residues 137,
310, and 561. These are conserved in all of the HEV strains
sequenced so far (1, 6, 18, 24, 26).
It has been suggested that pORF2 contains a signal se-
quence at its N-terminal end (21, 24). The putative signal
sequence is a 22-amino-acid stretch consisting of positively
charged residues (Arg) at the N-terminal end, a 14-residue
hydrophobic core, and a turn-inducing stretch of proline resi-
dues. However, direct proof of the presence of this signal
sequence is lacking. We have shown by means of pulse-chase
experiments that pORF2 is indeed synthesized as a larger
precursor, ppORF2, of about 82 kDa. This is subsequently
processed into the 74-kDa form and glycosylated to the mature
form, gpORF2, of 88 kDa. The approximately 82-kDa species
observed in tunicamycin and pulse-chase experiments are most
likely distinct from each other. While one may be an interme-
diate in the glycosylation pathway leading to gpORF2 (88
kDa), the other is the precursor which is processed to yield
pORF2. In Fig. 7A, both forms may be present but would not
resolve on the gel because of very similar sizes.
The various forms of pORF2 appear to run anomalously on
SDS-PAGE gels. On the basis of the primary sequence,
ppORF2 should be about 72 kDa but runs as an 82-kDa pro-
tein; its signal-cleaved form, which should be smaller, runs as a
74-kDa protein. Such anomalous mobility due to conforma-
tional and charge distribution effects has previously been ob-
served for several classes of proteins, including glycoproteins,
proline-rich proteins, maleylated proteins, calcium-binding
proteins, and histones (23). Apart from being a glycoprotein,
pORF2 is also rich in proline residues in its N-terminal region.
This is especially true for the signal sequence, which is about
one-third proline (7 of 22 residues). In fact, there appears to be
a far greater anomaly in the size of ppORF2 (82 versus 72
kDa) than in the size of its signal-cleaved form, pORF2 (74
versus 70 kDa).
The glycosylation pattern of a glycoprotein reflects the cel-
lular compartment through which it has passed during its syn-
thesis and processing. Our results with gpORF2 show that it is
completely sensitive to endoglycosidase H and therefore con-
tains only high-mannose residues. These structures are synthe-
sized in the endoplasmic reticulum and the cis Golgi compart-
ment (25). Thus, it appears that the processing of pORF2
occurs at the endoplasmic reticulum and that the protein is
subsequently transported either directly or through the cis
Golgi compartment to the cell surface. Consistent with this,
immunofluorescence localization showed pORF2 to be ex-
FIG. 8. In vitro processing of HEV proteins. (A) pSG-ORF2, pSG-ORF3, or both plasmids were used as templates in the in vitro coupled transcription-translation
system with (1) or without (2) canine pancreatic membranes. Synthesized proteins were separated by SDS–12% PAGE and visualized by fluorography. The size
markers are the same as those described in the legend to Fig. 7. (B) pORF2 synthesized in vitro in the presence of membranes was incubated in the absence (control)
or presence of endoglycosidase F, as described in the text. Samples were withdrawn after digestion for the times indicated, separated by SDS–7.5% PAGE, and
visualized by fluorography. The positions of pORF2, gpORF2, pORF3, and pORF3 dimer are indicated.
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pressed on the cell surface as well as in the cytoplasm. On the
cell surface, the protein appeared to be concentrated in some
regions, suggestive of an active process of association of pro-
tein subunits, perhaps into some higher-order forms. It has
been shown here that pORF2 subunits can homodimerize
through noncovalent interactions. Many positive-strand RNA
viruses replicate and assemble on membrane surfaces and uti-
lize a virally encoded RNA-binding capsid protein (4). pORF2,
quite basic (pI, ;10.3) in its amino-terminal half, may well
serve this purpose (21, 22). Though the replication strategy of
HEV has not been worked out, such a proposal would fit well
into the model proposed by Reyes et al. (22). It is not yet clear
what bearing the glycosylation of pORF2 has on its cell surface
localization and on the assembly of the HEV nucleocapsid.
This is currently being investigated with pORF2 mutants lack-
ing individual or all N-linked glycosylation sites.
The small ORF, ORF3, can code for a protein of 123 amino
acids (24). In accordance with this, we find a protein of 13.5
FIG. 9. Interactions between HEV proteins. (A and B) In vitro-synthesized pORF2 (A) and pORF3 (B) were treated with 5% 2-mercaptoethanol (bME) and/or
heated at 1008C for 2 min. The total mixture was separated by SDS–7.5% PAGE (A) or SDS–15% PAGE (B) and visualized by fluorography. The positions of size
markers (in kilodaltons) are indicated. (C) COS-1 cells were transfected with the indicated plasmids and labeled with [35S]methionine, and total lysates were
immunoprecipitated with the indicated antibodies. The proteins in washed immunoprecipitates were separated by SDS–12% PAGE and visualized by fluorography. The
positions of pORF2 and pORF3 are indicated. The size markers are the same as those described in the legend to Fig. 7.
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kDa expressed in cells transfected with ORF3 expression vec-
tors. This protein is localized in the cytoplasm and nonglyco-
sylated; it does not appear to undergo any modification that
would significantly alter its size. In its N-terminal half, pORF3
appears to contain two hydrophobic domains which have been
proposed to constitute either transmembrane segments or a
signal sequence followed by a transmembrane region (22). We
have provided clear evidence that pORF3 does not undergo
any significant processing to remove the proposed signal se-
quence.
Two forms of pORF3, 13.5 and 28 kDa, were routinely
observed in vitro, but only the 13.5-kDa form was seen in
transfected cells. One possibility is that the 28-kDa species
represents a highly stable dimeric form of pORF3. In support
of this, a similar species is also observed when pORF3 is
expressed in E. coli (18). Alternatively, this could be an artifact
of the in vitro system, whereby the ORF3 stop codon is skipped
and translation terminates downstream in the vector se-
quences. When a hexahistidine-pORF3 fusion protein is syn-
thesized in vitro, two forms are evident. One is the expected
monomeric (63His)pORF3 species of;17 kDa, and the other
is a species of ;28 kDa, significantly smaller than the expected
homodimer (7). This supports the second alternative. In ani-
mal cells, however, a cellular protein, which we have called 3IP,
was found to interact with pORF3. The fact that the in vitro-
expressed pORF3 monomer interacts very weakly with 3IP
suggests that this interaction takes place at the nascent chain
level inside the cell. The role of 3IP, if any, in pORF3 expres-
sion or function is not clear, considering that it coimmunopre-
cipitates with pORF3 from COS-1 and Huh-7 hepatoma cells,
not with pORF3 from HepG2 hepatoblastoma cells. However,
the differences between the two liver cell lines may be ex-
plained by their different stages of differentiation. We are
presently studying these homologous and heterologous inter-
actions of pORF3 in greater detail.
It is unknown whether pORF3 is a part of the virion. Here,
we tried to address this by looking for interactions between
pORF2 (the major capsid protein) and pORF3. Expression in
transfected cells and cross-immunoprecipitation with the re-
spective antibodies did not provide any evidence of an inter-
action between these two proteins. It is possible that such
interactions take place at the nascent chain level for these two
proteins or that the interactions are weak. Under both of these
circumstances, our experimental conditions are likely to over-
look such interactions. In the HEV genome, ORFs 2 and 3
overlap the entire stretch of ORF3, except for a 9-amino-acid
region at the N terminus of ORF3. Though at least two sub-
genomic RNAs coterminal with the 39 end of the HEV genome
have been reported (24), the subgenomic mRNA used for the
translation of either or both of these ORFs has not been
characterized. It is also possible that a single subgenomic
mRNA is utilized for the synthesis of both proteins, perhaps by
alternate initiator codon usage. In such a situation, the dynam-
ics of translation and protein-protein interactions at the nas-
cent chain level would be very distinct from those expected in
our experimental system in which these two proteins are ex-
pressed from different plasmids. Work currently in progress is
aimed in this direction.
How relevant are our findings to the infectious virus? Con-
tentious issues are the glycoprotein nature of pORF2 and the
fact that most viral glycoproteins are components of the virion
envelope. So far, there is no evidence to suggest that HEV
contains a lipid membrane. We propose that pORF2 is the
major constituent of the HEV nucleocapsid, which is assem-
bled at the cytoplasmic membrane. pORF2 is cotranslationally
translocated via its N-terminal signal sequence into the endo-
plasmic reticulum, where the signal is processed. The protein is
glycosylated and transported to the cell surface by a bulk flow
mechanism in the absence of any signals for retention in the
endoplasmic reticulum (19), e.g., the C-terminal KDEL pep-
tide found in endoplasmic reticulum lumenal proteins. The
glycosylation of pORF2 may be coincidental, considering its
passage through the endoplasmic reticulum (and perhaps the
cis Golgi compartment as well) and its three highly conserved
N-linked glycosylation sites. Some part of capsid assembly may
also occur in association with the endoplasmic reticulum, as
proposed by Reyes et al. (22), but final assembly and/or mat-
uration has to be cytoplasmic to account for the encapsidation
FIG. 10. Interaction between pORF3 and a cellular protein. (A) COS-1 cells were transfected with two independent clones of plasmid pSG-ORF3 or with plasmid
pSGI (Mock) and labeled with [35S]methionine, and total lysates were immunoprecipitated with anti-pORF3 antiserum. (B) In vitro-synthesized pORF3 was mixed with
the indicated amounts of [35S]methionine-labeled, untransfected COS-1 cell lysates. After incubation, immunoprecipitation with anti-pORF3 antiserum, and washing
with either RIPA or TST buffer, as described in the text, proteins were separated by SDS–15% PAGE and visualized by fluorography. The positions of the pORF3
monomer, the pORF3 dimer, pORF3, 3IP, and size markers are indicated.
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of HEV genomic RNA. At the cytoplasmic membrane, the
nucleocapsid self-assembles along with HEV positive-stranded
genomic RNA. It is not clear whether viral RNA is an absolute
requirement for nucleocapsid assembly, since Tsarev et al. (27)
have shown that pORF2 expressed in insect cells from a bacu-
loviral vector is able to form virus-like particles. It is also not
clear what role, if any, pORF3 plays in the assembly of the viral
nucleocapsid. In the absence of either a tissue culture or a
genomic RNA transfection system for HEV, we are trying to
answer some of these questions by using the COS-1 cell ex-
pression system described above.
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